BioSpace News Archive

Ampio Pharmaceuticals (NYSE American: AMPE), today announced that management will participate in a series of one-on-one meetings with institutional investors throughout the day at the Alliance Global Partners’ Virtual Summer Healthcare Symposium

Stuart Therapeutics, Inc. (“Stuart”), a clinical stage biopharmaceutical company conducting research and development of unique peptide therapeutics for ophthalmic diseases, today announced the start of patient enrollment for the company’s Phase 2 study of ST-100, in Dry Eye Eisease patients.

Increasing incidence of TB cases worldwide, technological advancements in vaccine discovery and developments, and implementation of favorable government policies are some key factors driving market growth.

New data from Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) for valemetostat, a potential first-in-class specific and potent dual inhibitor of EZH1 and EZH2, showed promising and durable tumor response in patients with relapsed/refractory peripheral T-cell lymphoma (PTCL) and adult T-cell leukemia/lymphoma (ATL)

Increasing use of bioresorbable polymers in medical sector, rising number of orthopedic surgeries performed across the globe, and advancements in orthopedic bioresorbable implants are some key factors driving market growth.

Increasing incidence of hearing loss and hearing impairment, growing global geriatric population, and technological advancements in cochlear implant are some key factors driving market growth.

Increasing incidence of dry mouth owing to side-effects of medicines, availability of a wide range of affordable dry mouth relief products, and rising awareness regarding dry mouth are key factors driving market growth.

Increasing launch of cost-efficient generic epinephrine products, growing incidence of anaphylaxis, and rising demand for epinephrine injections to treat cardiac arrest and asthma are some key factors driving market growth.

Increasing preference for fibrinogen concentrate over fresh-frozen plasma, rising incidence of bleeding disorders, and increasing number of fibrinogen product approvals are some key factors driving market growth.

At the forefront of the fight against COVID-19, Integral Molecular’s rapid Epitope Mapping technology is being used to pinpoint precise binding sites of therapeutic SARS-CoV-2 antibodies under development and can help determine their effectiveness against emerging viral variants.